NEOCARZINOSTATIN - REPORT OF A PHASE-II CLINICAL-TRIAL

  • 1 January 1981
    • journal article
    • research article
    • Vol. 65  (7-8) , 699-701
Abstract
Fifty-three patients received intensive treatment with neocarzinostatin in doses of 3500 U/m2 by i.v. bolus infusion daily for 5-14 days. The response rate for 22 patients with leukemia was 9%. One complete and 1 partial remission were observed among 9 patients with chronic myelogenous leukemia in blast cell crisis. None of the 31 patients with solid tumors responded to treatment. With this dose schedule, prolonged thrombocytopenia and cumulative bone marrow toxicity limit the intensity and duration of neocarzinostatin therapy. Acute allergic reactions occurred in 28% of the treatment courses; 3 patients developed anaphylaxis during the 2nd or 3rd course of therapy.

This publication has 0 references indexed in Scilit: